Pulse Biosciences (NASDAQ:PLSE) versus Its Competitors Head to Head Contrast

Pulse Biosciences (NASDAQ: PLSE) is one of 80 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its competitors? We will compare Pulse Biosciences to related companies based on the strength of its risk, profitability, analyst recommendations, earnings, valuation, institutional ownership and dividends.

Risk and Volatility

Pulse Biosciences has a beta of -0.17, indicating that its stock price is 117% less volatile than the S&P 500. Comparatively, Pulse Biosciences’ competitors have a beta of 1.44, indicating that their average stock price is 44% more volatile than the S&P 500.

Valuation & Earnings

This table compares Pulse Biosciences and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Pulse Biosciences N/A -$9.51 million -12.90
Pulse Biosciences Competitors $2.13 billion $235.11 million -37.88

Pulse Biosciences’ competitors have higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares Pulse Biosciences and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pulse Biosciences N/A -62.10% -57.47%
Pulse Biosciences Competitors -318.01% -23.72% -10.13%

Analyst Recommendations

This is a breakdown of current recommendations for Pulse Biosciences and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulse Biosciences 0 0 0 0 N/A
Pulse Biosciences Competitors 345 2026 3565 113 2.57

As a group, “Advanced Medical Equipment & Technology” companies have a potential upside of 6.18%. Given Pulse Biosciences’ competitors higher probable upside, analysts plainly believe Pulse Biosciences has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

9.3% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 51.5% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 6.7% of Pulse Biosciences shares are owned by insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


Pulse Biosciences competitors beat Pulse Biosciences on 8 of the 10 factors compared.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply